Management of Mild Crohn’s Disease in 2026

Auteurs-es

  • Nancy Fu

Résumé

Key Takeaways

1. Mild Crohn’s disease patients have limited anatomical disease involvement with no severe endoscopic lesions, and absence of stricturing, fistulizing or perianal features.  They are usually older, ambulatory, eating well and have no prior surgery, abnormal biochemistry or signs of systemic toxicity.
2. Non-pharmacological management for mild Crohn’s disease can include dietary interventions, NSAID and tobacco avoidance.  Pharmacotherapy may include budesonide, sulfasalazine and immunomodulators.  Mesalamines should not be used.
3. Mild Crohn’s disease can be managed with close monitoring only.  It should include regular clinical and biochemical evaluations with endoscopy, cross sectional studies and health maintenance assessments at recommended intervals.

Biographie de l'auteur-e

Nancy Fu

Dr. Nancy Fu is an Associate Clinical Professor at University of British Columbia.  Her practice focuses on inflammatory bowel disease, adolescent transition care, intestinal ultrasound training and applications, patient centered innovations and quality improvements. She co-leads the transition PACE project supported by Crohn’s and Colitis Canada. She is a faculty member of the GRIT program and a member of the IBD-GRS quality committee in the Canadian Gastroenterology Association. She participates in clinical research and GI residency training.

Références

Lichtenstein GR, Loftus EV, Afzali A, Long MD, Barnes EL, Isaacs KL, et al. ACG Clinical Guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2025;120(6):1225-1264. doi:10.14309/ajg.0000000000003465

Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E. Long-term evolution and predictive factors of mild inflammatory bowel disease. Scand J Gastroenterol. 2016;51(6):712–719. doi:10.3109/00365521.2015.1128965

Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists. Gastroenterology. 2021;161(1):47–65. doi:10.1053/j.gastro.2021.04.063

Siegel CA, Bernstein CN Identifying patients with inflammatory bowel diseases at high vs low risk of complications. Clin Gastroenterol Hepatol. 2019;18(6):1261-1267. doi:10.1016/j.cgh.2019.11.034

Turner D, Ricciuto A, Lewis A, D’Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570-1583. doi:10.1053/j.gastro.2020.12.031

Song K, Wu D. Shared decision-making in the management of patients with inflammatory bowel disease. World J Gastroenterol. 2022;28(26):3092-3100. doi:10.3748/wjg.v28.i26.3092

Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;2015(6):CD000296. doi:10.1002/14651858.CD000296.pub4

Kuenzig ME, Rezaie A, Seow CH, Otley AR, Steinhart AH, Griffiths AM, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;2014(8):CD002913. doi:10.1002/14651858.CD002913.pub3

Lim W-C, Wang Y, MacDonald JK, Hanauer S. Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database Syst Rev. 2016;7(7):CD008870. doi:10.1002/14651858.CD008870.pub2

Coward S, Kuenzig ME, Hazlewood G, et al. Comparative effectiveness of mesalamine, sulfasalazine, corticosteroids, and budesonide for the induction of remission in Crohn’s disease: a Bayesian network meta-analysis. Inflamm Bowel Dis. 2017;23(3):461–472. doi:10.1097/MIB.0000000000001023. Erratum in: Inflamm Bowel Dis. 2017;23(5):E25. doi:10.1097/MIB.0000000000001151. Corrected and republished in: Inflamm Bowel Dis. 2017;23(5):E26-E37. doi:10.1097/MIB.0000000000001158

Akobeng AK, Zhang D, Gordon M, MacDonald JK. Oral 5‐aminosalicylic acid for maintenance of medically‐induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2016;9(9):CD003715. doi:10.1002/14651858

Chande N, Patton PH, Tsoulis DJ, Thomas BS, MacDonald JK. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2015;2015(10):CD000067. doi:10.1002/14651858.CD000067.pub3

Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2014;2014(8):CD006884. doi:10.1002/14651858

Hashash JG, Elkins J, Lewis JD, Binion BD. AGA Clinical practice update on diet and nutritional therapies in patients with inflammatory bowel disease: expert review. Gastroenterology. 2024;166(3):521–532. doi:10.1053/j.gastro.2023.11.303

Chicco F, Magrì S, Cingolani A, Paduano D, Pesenti M, Zara F, et al. Multidimensional impact of Mediterranean diet on IBD patients. Inflamm Bowel Dis. 2021;27(1):1–9. doi: 10.1093/ibd/izaa097

Yanai H, Levine A, Hirsch A, Boneh RS, Kopylov U, Eran HB, et al. The Crohn’s disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn’s disease (CDED-AD): an open-label, pilot, randomised trial. Lancet Gastroenterol Hepatol. 2022;7(1):49–59. doi:10.1016/S2468-1253(21)00299-5

Jones J, Loftus EV Jr, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(11):1218–1224. doi:10.1016/j.cgh.2008.06.010

Grinman A, Ungar B, Lahat A, Kopylov U, Eliakim R, Ben-Horin S. Incidentally diagnosed asymptomatic Crohn’s Disease: a retrospective cohort study of long-term clinical outcomes. Crohns Colitis 360. 2022;4(3):otac034. doi: 10.1093/crocol/otac034

Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J. Crohn’s Colitis. 2019;13(3):273–284. doi:10.1093/ecco-jcc/jjy114

Ananthakrishnan AN, Adler J, Chachu KA, Nguyen NH, Siddique SM, Weiss JM, et al. AGA Clinical Practice Guideline on the role of biomarkers for the management of Crohn’s disease. Gastroenterology. 2023;165(6):1367–1399. doi:10.1053/j.gastro.2023.09.029

Chavannes M, Dolinger MT, Cohen-Mekelburg S, Abraham B. AGA clinical practice update on the role of intestinal ultrasound in inflammatory bowel disease: commentary. Clin Gastroenterol Hepatol. 2024;22(9):1790–1795.e1. doi:10.1016/j.cgh.2024.04.039

Moninuola OO, Milligan W, Lochhead P, Khalili H. Systematic review with meta-analysis: Association between acetaminophen and nonsteroidal Anti-inflammatory drugs (NSAIDs) and risk of Crohn’s disease and ulcerative colitis exacerbation. Aliment Pharmacol Ther. 2018;47(11):1428–1439. doi:10.1111/apt.14606

Lunney PC, Kariyawasam VC, Wang RR, Middleton KL, Huang T, Selinger CP, et al. Smoking prevalence and its influence on disease course and surgery in Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther. 2015;42(1):61–70. doi:10.1111/apt.13239

Syal G, Serrano M, Jain A, Cohen BL, Rieder F, Stone C, et al. Health maintenance consensus for adults with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(10):1552-1563. doi:10.1093/ibd/izab155

Téléchargements

Publié

2026-10-14

Comment citer

1.
Management of Mild Crohn’s Disease in 2026. Can IBD Today [Internet]. 14 oct. 2026 [cité 14 oct. 2026];4(Issue 2):30-4. Disponible à: https://canadianibdtoday.com/article/view/4-1-NancyFu

Numéro

Volume 4, Issue 2, Summer 2026

Rubrique

Articles

Licence

© Canadian IBD Today 2026

Licence Creative Commons

Cette œuvre est sous licence Creative Commons Attribution - Pas d'Utilisation Commerciale - Pas de Modification 4.0 International.

Comment citer

1.
Management of Mild Crohn’s Disease in 2026. Can IBD Today [Internet]. 14 oct. 2026 [cité 14 oct. 2026];4(Issue 2):30-4. Disponible à: https://canadianibdtoday.com/article/view/4-1-NancyFu